FDA
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Trevi Therapeutics (TRVI)
-
-
-
-
-
-
-
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Trevi Therapeutics publishes phase 2b chronic cough trial data in JAMA
-
-
-
-
-
-
-
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Trevi Therapeutics (TRVI)
-
-
-
-
-
-
-
Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
-
-
-
-
-
-
-
Trevi Therapeutics (TRVI) Reports Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio
-
334,271 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


